| Year |
Citation |
Score |
| 2020 |
Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, et al. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell. PMID 32531271 DOI: 10.1016/J.Ccell.2020.05.003 |
0.758 |
|
| 2019 |
Loonat AA, Martin ED, Sarafraz-Shekary N, Tilgner K, Hertz NT, Levin R, Shokat KM, Burlingame AL, Arabacilar P, Uddin S, Thomas M, Marber MS, Clark JE. p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701545R. PMID 31638431 DOI: 10.1096/Fj.201701545R |
0.706 |
|
| 2019 |
Hernández-Ortega S, Sánchez-Botet A, Quandt E, Masip N, Gasa L, Verde G, Jiménez J, Levin RS, Rutaganira FU, Burlingame AL, Wolfgeher D, Ribeiro MPC, Kron SJ, Shokat KM, Clotet J. Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex. Experimental & Molecular Medicine. 51: 44. PMID 30992425 DOI: 10.1038/S12276-019-0242-2 |
0.764 |
|
| 2018 |
Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology. PMID 29942081 DOI: 10.1038/S41589-018-0081-9 |
0.706 |
|
| 2017 |
Lazarus MB, Levin RS, Shokat KM. Discovery of new substrates of the elongation factor-2 kinase suggests a broader role in the cellular nutrient response. Cellular Signalling. 29: 78-83. PMID 27760376 DOI: 10.1016/J.Cellsig.2016.10.006 |
0.683 |
|
| 2016 |
Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL. An optimized chromatographic strategy for multiplexing in parallel reaction monitoring mass spectrometry: Insights from quantitation of activated kinases. Molecular & Cellular Proteomics : McP. PMID 27940637 DOI: 10.1074/Mcp.M116.058172 |
0.704 |
|
| 2016 |
Levin RS, Hertz NT, Burlingame AL, Shokat KM, Mukherjee S. Innate immunity kinase TAK1 phosphorylates Rab1 on a hotspot for posttranslational modifications by host and pathogen. Proceedings of the National Academy of Sciences of the United States of America. 113: E4776-83. PMID 27482120 DOI: 10.1073/Pnas.1608355113 |
0.739 |
|
| 2016 |
Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, ... ... Levin RS, et al. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Molecular Cancer Therapeutics. 15: 1472-84. PMID 27364904 DOI: 10.1158/1535-7163.Mct-15-0554 |
0.714 |
|
| 2016 |
Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery. 6: 727-39. PMID 27231123 DOI: 10.1158/2159-8290.Cd-15-1442 |
0.74 |
|
| 2016 |
Sansó M, Levin RS, Lipp JJ, Wang VY, Greifenberg AK, Quezada EM, Ali A, Ghosh A, Larochelle S, Rana TM, Geyer M, Tong L, Shokat KM, Fisher RP. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates. Genes & Development. 30: 117-31. PMID 26728557 DOI: 10.1101/Gad.269589.115 |
0.737 |
|
| 2016 |
Samson S, Zhou AY, Martins M, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan J, Levin R, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemens P, et al. Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities. Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-C88 |
0.687 |
|
| 2015 |
Schaffer BE, Levin RS, Hertz NT, Maures TJ, Schoof ML, Hollstein PE, Benayoun BA, Banko MR, Shaw RJ, Shokat KM, Brunet A. Identification of AMPK Phosphorylation Sites Reveals a Network of Proteins Involved in Cell Invasion and Facilitates Large-Scale Substrate Prediction. Cell Metabolism. 22: 907-21. PMID 26456332 DOI: 10.1016/J.Cmet.2015.09.009 |
0.74 |
|
| 2015 |
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discovery. 5: 154-67. PMID 25501949 DOI: 10.1158/2159-8290.Cd-14-0552 |
0.704 |
|
| 2014 |
Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Reports. 8: 1037-48. PMID 25127139 DOI: 10.1016/J.Celrep.2014.07.010 |
0.75 |
|
| 2014 |
Sos ML, Levin R, Gordan J, Oses-Prieto J, Webber J, Salt M, Hann B, Burlingame A, Mccormick F, Bandyopadhyay S, Shokat K. Abstract LB-216: Integrated analysis of differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-216 |
0.748 |
|
| 2014 |
Maas NL, Levin R, Singh N, Shokat K, Diehl JA. Abstract 486: Uncovering novel PERK signaling pathways through chemical-genetic screening Cancer Research. 74: 486-486. DOI: 10.1158/1538-7445.Am2014-486 |
0.603 |
|
| 2014 |
Sos M, Levin R, Gordan J, Oses-Prieto J, Webber J, Salt M, Hann B, Burlingame A, McCormick F, Bandyopadhyay S, Shokat K. 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer European Journal of Cancer. 50: 28-29. DOI: 10.1016/S0959-8049(14)70199-6 |
0.745 |
|
| Show low-probability matches. |